ASP2215 (gilteritinib)
Acute Myeloid Leukemia
ApprovedCommercial
Key Facts
About Astellas Pharma
Astellas Pharma Inc. is one of Japan's leading pharmaceutical companies with a global presence, dedicated to turning innovative science into value for patients. The company has built a strong portfolio of prescription medicines and is advancing multiple programs through clinical development, with particular expertise in urology, oncology, immunology, and neuroscience. Astellas is committed to becoming a global biopharmaceutical company by leveraging external innovation and strategic partnerships.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia Drugs
| Drug | Company | Phase |
|---|---|---|
| VANFLYTA (quizartinib) | Daiichi Sankyo | Approved |
| Vyxeos | Jazz Pharmaceuticals | Commercial |
| KT-253 | Kymera Therapeutics | Phase 1 |